These therapies are approved as first-line treatment for metastatic non-small cell lung cancer (NSCLC) and are effective against cells harboring certain EGFR mutations, the so-called activating mutations such as L858R mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.